Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 2014, Article ID 135357, 7 pages
http://dx.doi.org/10.1155/2014/135357
Clinical Study

Prognostic Value of VEGF in Patients Submitted to Percutaneous Coronary Intervention

1Instituto de Biociências e Bioengenharia (IBB), Instituto Superior Técnico, Universidade de Lisboa, Avenida Rovisco Pais 1, 1049-001 Lisboa, Portugal
2Serviço de Cardiologia, Hospital de Santa Marta, Centro Hospitalar de Lisboa Central, 1069-024 Lisboa, Portugal
3Carlota Saldanha Lab, Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, 1649-028 Lisboa, Portugal
4CESAM, Faculdade de Ciências, Universidade de Lisboa, 1749-016 Lisboa, Portugal
5CEDOC, Faculdade de Ciências Médicas, Universidade Nova de Lisboa, 1169-056 Lisboa, Portugal

Received 21 February 2014; Revised 17 June 2014; Accepted 20 June 2014; Published 7 July 2014

Academic Editor: Luisella Bocchio-Chiavetto

Copyright © 2014 Catarina Ramos et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

We examined the longitudinal changes of VEGF levels after percutaneous coronary intervention for predicting major adverse cardiac events (MACE) in coronary artery disease (CAD) patients. VEGF was measured in 94 CAD patients’ serum before revascularization, 1-month and 1-year after. Independently of clinical presentation, patients had lower VEGF concentration than a cohort of healthy subjects (median, IQ: 15.9, 9.0–264 pg/mL versus 419, 212–758 pg/mL; ) at baseline. VEGF increased to 1-month (median, IQ: 276, 167–498 pg/mL; ) and remained steady to 1-year (median, IQ: 320, 173–497 pg/mL; ) approaching control levels. Drug eluting stent apposition and previous medication intake produced a less steep VEGF evolution after intervention ( ). Baseline VEGF concentration <40.8 pg/mL conveyed increased risk for MACE in a 5-year follow-up. Results reflect a positive role of VEGF in recovery and support its importance in CAD prognosis.